A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy

Seminars in Perinatology

Volumn 39, Issue 7, 2015, Pages 548-555

  Clark, Shannon M ^a   Dunn, Holly E ^a   Hankins, Gary D V ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LABETALOL; NIFEDIPINE; ANTIHYPERTENSIVE AGENT; VASODILATOR AGENT;

AREA UNDER THE CURVE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLEFT LIP; CLEFT PALATE; CLINICAL PHARMACOLOGY; CONGENITAL DISORDER; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG USE; FETUS DISTRESS; GESTATION PERIOD; HEADACHE; HOT FLUSH; HUMAN; HYPOGLYCEMIA; HYPOTENSION; MATERNAL HYPERTENSION; NAUSEA; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SMALL FOR DATE INFANT; TACHYCARDIA; TREATMENT INDICATION; VOMITING; ADULT; BLOOD PRESSURE; FEMALE; HYPERTENSION, PREGNANCY-INDUCED; ORAL DRUG ADMINISTRATION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; LABETALOL; NIFEDIPINE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84945493590     PISSN: 01460005     EISSN: 1558075X     Source Type: Journal    
DOI: 10.1053/j.semperi.2015.08.011     Document Type: Review

References (26)

1. Tsatsaris V., Cabrol D., Carbonne B. Pharmacokinetics of tocolytic agents. Clin Pharmacokinet 2004, 43(13):833-844.
2. Ghanem F.A., Movahed A. Use of antihypertensive drugs during pregnancy and lactation. Cardiovasc Ther 2008, 26(1):38-49.
3. Magee L.A., Abalos E., von Dadelszen P., CHIPS Study Group, et al. How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol 2011, 72(3):394-401.
4. Fischer J.H., Sarto G.E., Hardman J., et al. Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. Clin Pharmacokinet 2014, 53(4):373-383.
5. Al Khaja K.A., Sequeira R.P., Al Khaja A.K., Damanhori A.H. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens 2014, 32(3):454-463.
6. Vest A.R., Cho L.S. Hypertension in pregnancy. Cardiol Clin 2012, 30(3):407-423.
7. Molvi S.N., Mir S., Rana V.S., Jabeen F., Malik A.R. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet 2012, 285(6):1553-1562.
8. Bateman B.T., Hernandez-Diaz S., Huybrechts K.F., et al. Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population. Hypertension 2012, 60(4):913-920.
9. Xie R.H., Guo Y., Krewski D., et al. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol 2014, 175:124-128.
10. Saotome T., Minoura S., Terashi K., et al. Labetalol in hypertension during the third trimester of pregnancy: Its antihypertensive effect and pharmacokinetic-dynamic analysis. J Clin Pharmacol 1993, 33(10):979-988.
11. Donnelly R., Macphee G.J. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol. Clin Pharmacokinet 1991, 21(2):95-109.
12. Daskas N., Crowne E., Shield J.P. Is labetalol really a culprit in neonatal hypoglycaemia?. Arch Dis Child Fetal Neonatal Ed 2013, 98(2):F185.
13. Giannubilo S.R., Bezzeccheri V., Cecchi S., et al. Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. Arch Gynecol Obstet 2012, 286(3):637-642.
14. Yakoob M.Y., Bateman B.T., Ho E., et al. The risk of congenital malformations associated with exposure to β-blockers early in pregnancy: a meta-analysis. Hypertension 2013, 62(2):375-381.
15. Kirsten R., Nelson K., Kirsten D., Heintz B. Clinical pharmacokinetics of vasodilators. Part II. Clin Pharmacokinet 1998, 35(1):9-36.
16. Rogers R.C., Sibai B.M., Whybrew W.D. Labetalol pharmacokinetics in pregnancy-induced hypertension. Am J Obstet Gynecol 1990, 162(2):362-366.
17. Magee L.A. Treating hypertension in women of child-bearing age and during pregnancy. Drug Safety 2001, 24(6):457-474.
18. Bateman B.T., Hernandez-Diaz S., Huybrechts K.F., et al. Outpatient calcium-channel blockers and the risk of postpartum haemorrhage: a cohort study. BJOG 2013, 120(13):1668-1676. [discussion 1676-7].
19. Magee L.A., Miremadi S., Li J., et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005, 193(1):153-163.
20. Khan K., Zamora J., Lamont R.F., et al. Safety concerns for the use of calcium channel blockers in pregnancy for the treatment of spontaneous preterm labour and hypertension: a systematic review and meta-regression analysis. J Matern Fetal Neonatal Med 2010, 23(9):1030-1038.
21. Kirsten R., Nelson K., Kirsten D., Heintz B. Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet 1998, 34(6):457-482.
22. Papatsonis D.N., Bos J.M., van Geijn H.P., Lok C.A., Dekker G.A. Nifedipine pharmacokinetics and plasma levels in the management of preterm labor. Am J Ther 2007, 14(4):346-350.
23. Sorkin E.M., Clissold S.P., Brogden R.N. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 1985, 30(3):182-274.
24. Foster T.S., Hamann S.R., Richards V.R., et al. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol 1983, 23(4):161-170.
25. Prevost R.R., Akl S.A., Whybrew W.D., Sibai B.M. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy 1992, 12(3):174-177.
26. Xie R.H., Guo Y., Krewski D., et al. Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. Eur J Obstet Gynecol Reprod Biol 2013, 171(2):281-285.